Finland · Delayed Price · Currency is EUR Solar Foods Oyj Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw the start of commercial operations, key partnerships, and Factory 02's launch. Revenue was modest, with increased operating loss due to scaling, but order book and funding grew. Regulatory approvals and further commercialization are expected in 2026.
-
Transitioning to commercial scale, the company secured key U.S. supply agreements and advanced Factory 02 planning, targeting the high-growth health and performance protein market. Financials show stable losses amid heavy investment, with strong sustainability positioning and positive customer feedback.
Fiscal Year 2024
-
Key milestones achieved include US regulatory approval, Factory 01 operational, and a new CEO appointed. Financials show a EUR 11 million annual loss, stable cash position, and new grant funding for R&D and US expansion. Positive EBITDA targeted by 2030.
-
The company is scaling up hydrogen fermentation technology to produce Solein, a sustainable protein targeting the U.S. health and performance market first, with plans for global expansion. Factory 02 will be built in phases, aiming for positive EBITDA by 2030 and long-term annual EBITDA above EUR 100 million.
-
Key milestones achieved in H1 2024 include Factory 01 launch, US regulatory approval, and Nasdaq listing. Financially, the company maintains a strong cash position and expects profitability after scaling new factories. Commercialization and global expansion are the focus for the next strategy period.